Sat-156 Renal, Cardiovascular, and Safety Outcomes of Canagliflozin According to Baseline Albuminuria: A Credence Secondary Analysis

Abstract

Conclusions: Metformin levels are useful for predicting the development of lactic acidosis, with the cutoff value of 5 mcg / mL, representing an analytical parameter of an important value in the adjustment and optimization of the use of M in population with CKD given the current recommendations of international guidelines, minimizing the risk of development of Metformin-associated Lactic Acidosis.

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial

“…These data are consistent with the well-known association between UACR and kidney outcomes [ 8 , 21 – 24 ]. Similar results were also observed in the CREDENCE trial, with substantially increased rates of kidney and cardiovascular events among patients with type 2 diabetes and CKD and a UACR above 339.0 mg/mmol (3000 mg/g) [ 25 ]. Despite the advanced stage of kidney disease and vulnerable population included in the DAPA-CKD trial, adverse and serious adverse event rates were similar with dapagliflozin compared with placebo across all categories of baseline UACR.…”

The Promise of Tubule Biomarkers in Kidney Disease: A Review

“…Figure 2. Examples of potential use cases for kidney tubule injury and dysfunction biomarkers in clinical practice, for the purposes of prognosis, 20,27,37 treatment selection, 36 monitoring for treatment effectiveness, 41,42 monitoring for medication safety, 29,43 and distinguishing injury from hemodynamic causes of declining eGFR. [33][34][35] Abbreviations: CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus.…”

Reported cases of end-stage kidney disease—United States, 2000–2019

“…In persons with diabetes, ACE inhibitors and ARBs lower blood pressure, reduce albuminuria, and slow the decline in kidney function 5 . Other agents such as SGLT2 inhibitors have been shown to reduce the risks for cardiovascular disease and progression of chronic kidney disease in patients with type 2 diabetes, in addition to lowering blood glucose 6 . However, the number of patients with newly treated ESKD from diabetes is likely to continue to increase with the increasing number of persons with diagnosed diabetes 4…”

“…Higher percentage changes in both incident and prevalent ESKD cases were among Asian, Hispanic, and Native Hawaiian or other Pacific Islander persons and among cases with hypertension or diabetes as the primary cause. Interventions to improve care and better manage ESKD risk factors among persons with diabetes and hypertension, along with increased use of therapeutic agents such as angiotensin‐converting enzyme (ACE) inhibitors, angiotensin‐receptor blockers (ARB), and sodium‐glucose cotransporter 2 (SGLT2) inhibitors shown to have kidney‐protective benefits 5,6 might slow the increase and eventually reverse the trend in incident ESKD cases.…”